Interim efficacy and safety of PD-1 inhibitors in preventing recurrence of hepatocellular carcinoma after interventional therapy

Interim efficacy and safety of PD-1 inhibitors in preventing recurrence of hepatocellular carcinoma after interventional therapy

IntroductionLocoregional interventional therapy including transcatheter arterial chemoembolization (TACE) and ablation are the current standard of treatment for early-to-mid-stage hepatocellular carcinoma (HCC). However, questions remain unanswered regarding the management of recurrence after locore...

Full description

Bibliographic Details
Main Authors: Wenying Qiao, Qi Wang, Caixia Hu, Yinghua Zhang, Jianjun Li, Yu Sun, Chunwang Yuan, Wen Wang, Biyu Liu, Yonghong Zhang
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-10-01
Series:Frontiers in Immunology
Subjects:
hepatocellular carcinoma
PD-1 inhibitors
TACE
ablation
immune
recurrence
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2022.1019772/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2022.1019772/full

Similar Items